How to Treat Anemia After Surgery

Treating anemia after surgery depends on how severe the drop in hemoglobin is and what caused it, but the most common approaches are intravenous iron supplementation, carefully considered blood transfusion, and in some cases erythropoiesis-stimulating agents that nudge the body to produce more red blood cells. Postoperative anemia is extraordinarily common, affecting the vast majority of patients after major procedures, yet it often goes under-treated because clinicians expect hemoglobin to recover on its own. The evidence over the past decade has reshaped how surgical teams approach it, with a strong push toward fixing iron stores early, transfusing less often but more deliberately, and bundling several strategies together under what is now called patient blood management.

Why Anemia After Surgery Is So Common

Surgery causes blood loss. That much is obvious. But the scale of postoperative anemia surprises most people. In a retrospective study at a Brazilian university hospital, roughly 60% of patients were already anemic before their elective surgery, and that rate climbed to nearly 95% afterward, with average hemoglobin levels dropping to around 9.4 g/dL.¹ Those numbers reflect a perfect storm: the blood lost during the operation itself, the dilutional effect of intravenous fluids given during and after surgery, and the body’s inflammatory response, which locks iron inside storage cells and makes it temporarily unavailable for building new red blood cells.

That inflammatory mechanism is worth understanding because it explains why anemia can linger for weeks. When tissue is cut and healing begins, the body ramps up production of hepcidin, a hormone that blocks iron absorption in the gut and traps iron in storage. This is a normal defense against infection (bacteria need iron too), but it also means the bone marrow is starved of the raw material it needs to make hemoglobin. So even if you eat iron-rich foods or take oral iron pills, your body may not be able to use much of that iron for the first week or two after a major procedure.

Why It Matters More Than People Think

Postoperative anemia is not just an inconvenient lab number. After major abdominal surgery, patients with postoperative anemia had about a 50% higher adjusted risk of death or disability within 90 days compared with patients whose hemoglobin stayed normal, at rates of roughly 18% versus 9%.² Anemic patients in that study also had higher rates of septic complications, unplanned ICU admissions, and poorer self-reported recovery quality at both 3 and 30 days after surgery.

The picture is similar in other surgical populations. In older cardiac surgery patients, lower postoperative hemoglobin was tied to worse mental health-related quality of life three months out.³ And large observational studies involving over 600,000 surgical patients have established that anemia going into surgery is itself an independent risk factor for complications, longer hospital stays, and the need for blood transfusion afterward.⁴ The takeaway for patients is that anemia is not something to wait out passively. Treating it, ideally before it gets severe, has real consequences for how quickly and completely you recover.

Intravenous Iron Is the Strongest Post-Surgery Option

If your surgical team decides to treat postoperative anemia with iron, the intravenous route is the one backed by the most convincing data. A systematic review and meta-analysis published in 2025 found that IV iron raised hemoglobin levels significantly after surgery, while oral iron did not produce a meaningful increase compared with control groups.⁵ This makes physiological sense given what happens to iron absorption after an operation. The inflammatory surge and elevated hepcidin mean that oral iron largely sits in the gut without being absorbed, while IV iron bypasses that blockade entirely and delivers iron directly to the bloodstream.

A head-to-head trial in cardiac surgery patients illustrates the gap. Patients given IV iron after surgery had higher hemoglobin levels than those given oral iron, and none of the IV iron recipients had depleted ferritin stores at follow-up, compared with about a quarter of the oral iron group.⁶ Another trial, in patients recovering from abdominoplasty after bariatric surgery, showed a statistically significant advantage for IV iron sucrose over oral iron at eight weeks, with no adverse events in the IV group, whereas nearly a third of oral iron recipients experienced constipation, diarrhea, or nausea.⁷

Safety is a common concern with IV iron, but the risk profile with current formulations is reassuring. Minor infusion reactions are uncommon and generally self-limiting, caused by trace amounts of free iron rather than true allergy. Severe hypersensitivity reactions are exceedingly rare, occurring in fewer than 1 in 250,000 administrations.⁸ A meta-analysis of preoperative IV iron similarly found no increased incidence of serious or non-serious adverse events compared with controls.⁹ The infusion does need to happen in a facility where staff can manage the rare acute reaction, but for the vast majority of patients, IV iron is well tolerated and effective.

Where Oral Iron Fits In

Given that IV iron outperforms oral iron in the immediate post-surgical window, you might wonder why oral iron is ever used. The practical reasons are cost, convenience, and timing. Not every patient needs iron during the narrow inflammatory window right after surgery. For patients whose anemia is milder, who are weeks out from their procedure, or who are managing recovery at home, oral iron is a reasonable and much cheaper option. The inflammatory hepcidin response typically fades within a couple of weeks, reopening the gut’s ability to absorb iron.

Even in non-surgical settings, though, oral iron has a messy reputation. It causes stomach upset, constipation, and nausea in a meaningful fraction of people, and these side effects often lead patients to stop taking it. One strategy that has gained traction is alternate-day dosing. A study in iron-deficient anemic women found that iron absorption was 40–50% higher when pills were taken every other day instead of daily, because each dose triggers a temporary hepcidin spike that blunts absorption of the next day’s dose.¹⁰ In theory, you can give twice the dose on alternate days and absorb roughly twice as much total iron as from daily dosing.

A large study of US veterans with iron deficiency anemia, however, complicated this picture. Patients who took iron on multiple days per week (but not daily) actually saw faster hemoglobin recovery than either daily or strict alternate-day dosers.¹¹ The alternate-day group in that study did not outperform daily dosing. So the optimal oral iron schedule remains somewhat unsettled, but most experts agree that taking iron pills less often, with a larger dose per pill, tends to be better tolerated without sacrificing much absorption once the acute inflammatory phase has passed.

Blood Transfusion and When It Makes Sense

Transfusion is the fastest fix for severe anemia. A unit of red blood cells raises hemoglobin by roughly 1 g/dL in an average-sized adult, and the effect is immediate. But transfusion carries its own set of risks, including transfusion reactions that range from mild fevers to rare but serious complications like immune-mediated hemolysis and lung injury.¹² Transfusion has also been linked in observational data to higher rates of postoperative infection and immune suppression, a phenomenon sometimes called transfusion-related immunomodulation.¹³

This is why the field has moved decisively toward restrictive transfusion triggers, meaning doctors wait until hemoglobin drops to a lower threshold before transfusing. A Cochrane review covering over 20,000 participants found that restrictive strategies reduced the chance of receiving at least one transfusion by about 41% without increasing the risk of 30-day mortality, cardiac events, stroke, or blood clots.¹⁴ The evidence is remarkably consistent across surgical settings. In high-risk elderly patients after hip surgery, a liberal strategy showed no benefit over a restrictive one for death, walking ability, or in-hospital complications.¹⁵ In cardiac surgery, outcomes at six months were essentially identical between the two strategies.¹⁶ A meta-analysis focused on hip and knee surgery found no differences in mortality, pneumonia, wound infection, heart attack, or heart failure between restrictive and liberal thresholds.¹⁷

What this means in practice is that most surgical patients do not need a transfusion unless hemoglobin falls below roughly 7–8 g/dL, or they develop symptoms like a racing heart, dizziness, or dangerously low blood pressure. The days of automatically transfusing anyone whose hemoglobin dipped below 10 are largely over. An interesting wrinkle, though, is that randomized trials have not shown clear quality-of-life advantages for either strategy, so the decision often hinges on symptom burden rather than a fixed number.¹⁸

Erythropoiesis-Stimulating Agents After Surgery

Erythropoietin (EPO) and related drugs stimulate the bone marrow to produce more red blood cells. They are a mainstay in treating anemia from chronic kidney disease, and there is a logical appeal to using them after surgery when the body’s natural red cell production is suppressed. But the evidence for postoperative use is surprisingly weak. A trial combining IV iron with EPO in orthopedic surgery patients found that the combination was ineffective at correcting postoperative anemia beyond slightly higher reticulocyte counts in the first week, with no improvement in iron mobilization or meaningful hemoglobin recovery.¹⁹ An earlier study reached the same conclusion: IV iron alone or combined with EPO did not accelerate early recovery from postoperative anemia.²⁰

The safety profile adds another layer of caution. EPO carries a theoretical risk of blood clots, though a prospective study in hip replacement patients using a clot-monitoring technique found no significant increase in thromboembolism events with EPO compared to controls.²¹ A systematic review examining adverse events from iron and EPO therapy in anemic surgical patients found that the overall certainty of the safety evidence was very low, making it hard to draw firm conclusions either way.²² The bottom line is that EPO is sometimes used before surgery to build up hemoglobin in advance, but using it after surgery to treat established anemia has not panned out in trials and is not a routine recommendation.

Patient Blood Management Programs

Rather than treating postoperative anemia as a single problem with a single drug, the most effective approach bundles multiple strategies together. Patient blood management (PBM) programs typically rest on three pillars: detect and treat anemia before surgery, minimize blood loss during and after the operation, and tolerate lower hemoglobin levels when it is safe to do so rather than reflexively transfusing.²³

These programs produce striking results when implemented rigorously. One hospital that introduced a blood management protocol for hip and knee replacements saw transfusion rates drop from 23% to about 4% for hips, and from nearly 7% to 0.5% for knees, while the median hospital stay fell from 6 days to 3.²⁴ A similar before-and-after study in major orthopedic surgery found that implementing a PBM protocol cut the proportion of patients receiving transfusions from 13% to 3% and reduced the fraction discharged with a hemoglobin below 10 g/dL from 25% to 14%.²⁵

The key insight from PBM is that the best treatment for postoperative anemia often starts before you even reach the operating room. If a patient is found to be iron-deficient at a preoperative visit weeks ahead of time, oral or IV iron can raise hemoglobin before the surgical blood loss occurs, giving the patient a bigger buffer. During surgery, techniques like tranexamic acid (a drug that slows clot breakdown and reduces bleeding) and meticulous surgical hemostasis further protect the hemoglobin level. Together these measures mean fewer patients arrive in the recovery ward with dangerously low blood counts in the first place.

Special Situations That Change the Approach

Some surgeries create unique nutritional challenges that make anemia harder to treat. Bariatric procedures, for instance, alter the anatomy of the stomach and small intestine, which can impair absorption of iron, vitamin B12, folate, and copper for months or years afterward.²⁶ For these patients, oral iron may be permanently unreliable, and periodic IV iron infusions or B12 injections become part of long-term follow-up rather than a one-time treatment.

Patients who decline blood transfusion for religious or personal reasons present another challenge. For them, the focus shifts entirely toward maximizing the body’s own blood-producing capacity and minimizing any further losses. That means aggressive preoperative optimization with IV iron and sometimes EPO, meticulous surgical technique, use of blood-salvage devices that collect and return a patient’s own blood during the operation, and accepting lower hemoglobin thresholds postoperatively while supporting the patient with supplemental oxygen and careful fluid management.²⁷ These “bloodless surgery” strategies have expanded the toolkit for all patients, not just those who decline transfusion.

Older adults deserve special mention because they tolerate anemia poorly. Frailty, pre-existing heart disease, and reduced physiological reserve mean that a hemoglobin level that a healthy 40-year-old might barely notice can leave a 75-year-old bedbound and confused. In older cardiac surgery patients, lower postoperative hemoglobin was associated with reduced mental quality of life, a dimension that younger patients rarely report.³ Early functional outcomes also suffer: after hip arthroplasty, a faster-paced recovery program showed that postoperative hemoglobin levels explained a small but real portion of how far patients could walk at two weeks.²⁸ For older patients, the argument for proactive anemia treatment, rather than watchful waiting, is strongest.

What Recovery Actually Looks Like

Even with treatment, hemoglobin does not bounce back overnight. Red blood cells take about three to four weeks to mature from precursors in the bone marrow to functional cells circulating in the blood. IV iron can replenish stores quickly, but the bone marrow still needs time to use that iron to build new hemoglobin. Most patients notice gradual improvement in energy and exercise tolerance over four to eight weeks, with hemoglobin levels typically normalizing by two to three months if iron stores are adequate and there is no ongoing blood loss.

During this recovery phase, symptoms like fatigue, shortness of breath on exertion, and reduced stamina are normal and expected. Light activity is generally encouraged because it promotes circulation and helps the body signal its need for more red blood cells. What you should not do is assume that persistent exhaustion months after surgery is just “normal recovery.” If you are still wiped out eight weeks after your operation, it is worth asking your doctor to check a complete blood count and iron studies. Ongoing anemia at that point may signal an unresolved iron deficit, an unrecognized source of bleeding, or a nutritional deficiency like B12 or folate that needs separate treatment.

Emerging Drug Classes on the Horizon

The newest entrants in anemia treatment are hypoxia-inducible factor prolyl hydroxylase inhibitors, oral drugs that trick the body into responding as though it is at high altitude, ramping up natural erythropoietin production and improving iron absorption simultaneously. Roxadustat and desidustat are the best-known examples, and they are already approved in some countries for anemia in chronic kidney disease. Case reports have begun exploring their use in refractory post-transplant anemia, with one description of a kidney transplant patient with parvovirus-related anemia showing sustained hemoglobin improvement on desidustat after failing other therapies.²⁹ Whether these drugs will find a role in routine postoperative anemia management is still an open question, and no large surgical trials have been completed yet. But the mechanism is appealing because it addresses both the iron-availability problem and the red-cell-production problem in a single oral pill, which would be a genuine advance over the current approach of giving IV iron for one and EPO for the other.

Cost is another consideration that may shape adoption of newer therapies. Even among existing IV iron formulations, expense varies considerably. A pharmacoeconomic analysis at a cardiac rehabilitation center found that switching from one IV iron product to a newer oral-bioavailable iron formulation saved roughly €49 per patient, which added up to over €4,000 annually for about 55 patients.³⁰ As hospitals look to PBM programs for cost savings alongside clinical improvements, the economic profile of each therapy becomes part of the treatment decision, not just its effect on hemoglobin numbers.